News & Views | Published:


To see or not to see — what renders prostate cancer visible?

Nature Reviews Urologyvolume 16pages274275 (2019) | Download Citation

Multiparametric MRI (mpMRI) has revolutionized prostate cancer diagnosis and risk stratification, but the question remains regarding what it is that we see (or don’t see) on mpMRI. A new study by Houlahan and colleagues now offers insight into the molecular characteristics of a tumour that influence mpMRI visibility.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Hamdy, F. C. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).

  2. 2.

    Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in prostate cancer - 29-year follow-up. N. Engl. J. Med. 379, 2319–2329 (2018).

  3. 3.

    Ahmed, H. U. et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 389, 815–822 (2017).

  4. 4.

    Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767–1777 (2018).

  5. 5.

    Houlahan, K. E. et al. Molecular hallmarks of multiparametric magnetic resonance imaging visibility in prostate cancer. Eur. Urol. (2019).

  6. 6.

    Li, H. et al. Dynamics of angiogenesis and cellularity in rabbit VX2 tumors using contrast-enhanced magnetic resonance imaging and diffusion-weighted imaging. Oncol. Lett. 15, 2978–2984 (2018).

  7. 7.

    Liang, S. et al. Information-based ranking of 10 compartment models of diffusion-weighted signal attenuation in fixed prostate tissue. NMR Biomed. 29, 660–671 (2016).

  8. 8.

    Devine, W. et al. Simplified luminal water imaging for the detection of prostate cancer from multiecho T2 MR images. J. Magn. Reson. Imaging (2018).

  9. 9.

    Martin, D. T. et al. Prostate cancer genomic classifier relates more strongly to gleason grade group than prostate imaging reporting and data system score in multiparametric prostate magnetic resonance imaging-ultrasound fusion targeted biopsies. Urology 125, 64–72 (2019).

  10. 10.

    Moore, C. M. et al. The effect of dutasteride on magnetic resonance imaging defined prostate cancer: MAPPED-a randomized, placebo controlled, double-blind clinical trial. J. Urol. 197, 1006–1013 (2017).

Download references


M.E. receives research support from the United Kingdom’s National Institute of Health Research (NIHR) and the University College London Hospital (UCLH)–UCL Biomedical Research Centre. He has been an NIHR Senior Investigator since 2013.

Author information


  1. Division of Surgery and Interventional Science, University College London, London, UK

    • Mark Emberton


  1. Search for Mark Emberton in:

Competing interests

The author declares no competing interests.

Corresponding author

Correspondence to Mark Emberton.

About this article

Publication history


Issue Date


Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing